Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib

뉴스 본문을 불러오고 있어요.

Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib | 웨이프 WAPE

Kairos Pharma Announces Interim Safety Data From Phase I Trial Of Carotuximab In Combination With AstraZeneca's Osimertinib To Resensitize Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer Who Became Resistant To Osimertinib

기사 요약

관련 종목

댓글 —